Anebulo Pharmaceuticals logo

Anebulo PharmaceuticalsNASDAQ: ANEB

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

07 May 2021

Website:

http://www.anebulo.com

Next earnings report:

20 September 2024

Last dividends:

N/A

Next dividends:

N/A

Market cap

$70.80 M
-60%vs. 3y high
39%vs. sector

PE ratio

-
-vs. 3y high
-vs. sector

PB ratio

14.20
-12%vs. 3y high
95%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

regular market | Fri, 28 Jun 2024 13:30:00 GMT
$2.73+$0.10(+3.80%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$0.06-$0.13

Revenue

Revenue target

--
No data over the past 3 years

Revenue

Net income

--$1.65 M

Analysts recommendations

Total assets

Total liabilities

$6.00 M$1.01 M

Institutional Ownership

Included in screeners

Small cap companies
Top performing stocks today
Stocks with price above SMA 50
Stocks with low beta
Price lower than analysts target
Analysts recommendations: buy
Growing shares outstanding

Similar companies

Gritstone bio logo

Gritstone bio (GRTS)

SELLAS Life Sciences logo

SELLAS Life Sciences (SLS)

Champions Oncology logo

Champions Oncology (CSBR)

enVVeno Medical logo

enVVeno Medical (NVNO)

Landos Biopharma logo

Landos Biopharma (LABP)

Anixa Biosciences logo

Anixa Biosciences (ANIX)

Genelux (GNLX)

Spero Therapeutics logo

Spero Therapeutics (SPRO)

ANEB Latest News

Are Medical Stocks Lagging Anebulo Pharmaceuticals (ANEB) This Year?
Zacks Investment Research19 October 2023 Sentiment: NEUTRAL

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Conmed (CNMD) have performed compared to their sector so far this year.

Anebulo (ANEB) Gains on Positive FDA Response for ANEB-001
Zacks Investment Research22 August 2023 Sentiment: POSITIVE

Anebulo (ANEB) gains on positive FDA response for the phase III development of its lead candidate ANEB-001 for treating patients with acute cannabinoid intoxication.

Is Anebulo Pharmaceuticals (ANEB) Outperforming Other Medical Stocks This Year?
Zacks Investment Research12 June 2023 Sentiment: POSITIVE

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Aquestive Therapeutics (AQST) have performed compared to their sector so far this year.

Has Anebulo Pharmaceuticals (ANEB) Outpaced Other Medical Stocks This Year?
Zacks Investment Research24 May 2023 Sentiment: POSITIVE

Here is how Anebulo Pharmaceuticals, Inc. (ANEB) and Ligand Pharmaceuticals (LGND) have performed compared to their sector so far this year.

What type of business is Anebulo Pharmaceuticals?

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.

What sector is Anebulo Pharmaceuticals in?

Anebulo Pharmaceuticals is in the Healthcare sector

What industry is Anebulo Pharmaceuticals in?

Anebulo Pharmaceuticals is in the Biotechnology industry

What country is Anebulo Pharmaceuticals from?

Anebulo Pharmaceuticals is headquartered in United States

When did Anebulo Pharmaceuticals go public?

Anebulo Pharmaceuticals initial public offering (IPO) was on 07 May 2021

What is Anebulo Pharmaceuticals website?

https://www.anebulo.com

Is Anebulo Pharmaceuticals in the S&P 500?

No, Anebulo Pharmaceuticals is not included in the S&P 500 index

Is Anebulo Pharmaceuticals in the NASDAQ 100?

No, Anebulo Pharmaceuticals is not included in the NASDAQ 100 index

Is Anebulo Pharmaceuticals in the Dow Jones?

No, Anebulo Pharmaceuticals is not included in the Dow Jones index

When does Anebulo Pharmaceuticals report earnings?

The next expected earnings date for Anebulo Pharmaceuticals is 20 September 2024